The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative approaches for cancer diagnostics and therapy. These approaches evaluate underlying biology and utilize nanotechnology, chemistry and physics interrogated with modern imaging methods. The lab focuses currently several avenues: (i) the utilization of nanoparticles for cancer therapy; (ii) novel imaging approaches such as Cerenkov and optoacoustic imaging and (iii) the biology of PSMA both in prostate cancer and neovasculature using a tumor-on-chip microfluidic chip system.
Jan Grimm, MD, PhD
Research FocusRadiologist and Nuclear Medicine physician Jan Grimm develops novel approaches for improved diagnosis, monitoring and therapy of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- Photoactivatable Prodrug of Doxazolidine Targeting Exosomes. Tamura R, Balabanova A, Frakes SA, Bargmann A, Grimm J, Koch TH, Yin H. J Med Chem. 2019 Feb 13. doi: 10.1021/acs.jmedchem.8b01508.
- Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Roberts S, Andreou C, Choi C, Donabedian P, Jayaraman M, Pratt EC, Tang J, Pérez-Medina C, Jason de la Cruz M, Mulder WJM, Grimm J, Kircher M, Reiner T. Chem Sci. 2018 May 18;9(25):5646-5657. doi: 10.1039/c8sc01706a. eCollection 2018 Jul 7.